# Safety and Pharmacokinetics Study of Single Ascending Doses of VV116 in Healthy Volunteers

> **NCT05227768** · PHASE1 · COMPLETED · sponsor: **Vigonvita Life Sciences** · enrollment: 38 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** VV116 25mg Group
- **DRUG:** VV116 200mg Group
- **DRUG:** VV116 400mg Group
- **DRUG:** VV116 800mg Group
- **DRUG:** VV116 1200mg Group

## Key facts

- **NCT ID:** NCT05227768
- **Lead sponsor:** Vigonvita Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-11
- **Primary completion:** 2022-01-13
- **Final completion:** 2022-01-13
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2022-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05227768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05227768, "Safety and Pharmacokinetics Study of Single Ascending Doses of VV116 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05227768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*